Dickey R F
Cutis. 1976 Jan;17(1):179-83.
Six separate investigators following the methodology stipulated in a common protocol provided a data base of 124 patients with Rhus dermatitis, other contact dermatitis, or atopic dermatitis. In this double-blind study, one or two 1 ml (4.0 mg/ml) intramuscular injections of the new sodium phosphate ester of betamethasone was compared with dexamethasone sodium phosphate in the treatment of the signs and symptoms common to these disorders. The comparably balanced groups responded dramatically to both drugs. Within 24 hours the mean scores of all symptoms and patients' overall condition were reduced appreciable. Pruritus, burning, inflammation and other typical symptoms and signs each responded well. The significant beneficial differences were observed most often in patients on betamethasone. There were no treatment failures and no side effects in this short-term trial.
六名独立研究人员按照一份通用方案规定的方法，提供了一个包含124例漆树性皮炎、其他接触性皮炎或特应性皮炎患者的数据库。在这项双盲研究中，将一或两次1毫升（4.0毫克/毫升）的倍他米松新磷酸酯肌内注射与地塞米松磷酸钠用于治疗这些疾病共有的体征和症状进行了比较。两组平衡相当的患者对两种药物均有显著反应。在24小时内，所有症状的平均评分以及患者的整体状况均有明显改善。瘙痒、灼痛、炎症及其他典型症状和体征均反应良好。倍他米松治疗的患者中最常观察到显著的有益差异。在这项短期试验中没有治疗失败的情况，也没有副作用。
